Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746958 | 0.89 | NOD1 (0.48) | KMT2APOLBNOD1 | |
| SCHEMBL17746954 | 0.89 | NOD1 (0.48) | KMT2APOLBNOD1 | |
| SCHEMBL22996115 | 0.87 | KMT2A (0.35) | KMT2APOLBHDAC2L3MBTL1TAS1R3 | |
| SCHEMBL20009714 | 0.85 | NOD1 (0.48) | HDAC2NOD1 | |
| SCHEMBL17747010 | 0.83 | KMT2A (0.44) | KMT2APOLBNOD1 | |
| SCHEMBL17747023 | 0.83 | KMT2A (0.44) | KMT2APOLBNOD1 | |
| SCHEMBL20009571 | 0.81 | HDAC8 (0.35) | KMT2APOLBHDAC2L3MBTL1 | |
| SCHEMBL17747018 | 0.79 | HDAC8 (0.43) | KMT2APOLB | |
| SCHEMBL17746994 | 0.79 | HDAC8 (0.43) | KMT2APOLB | |
| SCHEMBL17747020 | 0.79 | HDAC8 (0.43) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885POLB 2800/4885HDAC2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.